SCHEMBL4873267

SCHEMBL4873267

O=C(O)c1cc2c(s1)c(C1CCCCC1)c(-c1ccc3nc(-c4cccc(F)c4)ccc3c1)n2Cc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.34
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
CYP2D6 P10635 2/20 0.32
HRH1 P35367 2/20 0.32
KMO O15229 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
UBE2M P61081 1/20 0.32
DCUN1D1 Q96GG9 1/20 0.32
GRM2 Q14416 1/20 0.31
PLK4 O00444 1/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31
CHEK2 O96017 1/20 0.31
CDK1 P06493 1/20 0.31
PIM1 P11309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879012 0.93 ALOX5AP (0.35) ALOX5APMAPTCYP2D6HRH1GRM2
SCHEMBL4866901 0.91 GRIN1 (0.33) ALOX5APGRIN1GRIN2BKMOMDM2
SCHEMBL4876388 0.89 ALOX5AP (0.38) ALOX5APDYRK1AMDM2
SCHEMBL4872012 0.88 MDM2 (0.35) ALOX5APCDK2GSK3BMDM2AKT1
SCHEMBL4873278 0.87 GRIN1 (0.37) ALOX5APGRIN1GRIN2BKMOALDH1A1
SCHEMBL4877200 0.86 KDM4E (0.33) ALOX5APMAPTALDH1A1
SCHEMBL4875175 0.86 ERCC5 (0.38) ALOX5AP
SCHEMBL4868085 0.86 F10 (0.33) ALOX5APALDH1A1GAA
SCHEMBL4867590 0.86 ALOX5AP (0.35) ALOX5APKMOMDM2
SCHEMBL4876346 0.86 GRIN2B (0.35) GRIN2BMAPTCYP2D6HRH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 ALOX5AP 3943/4885GRIN1 2653/4885GRIN2B 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.